Lunit Signs Research Agreement With Summit Therapeutics for AI-Powered Cancer Analysis

• Lunit entered a research agreement with Summit Therapeutics to evaluate its SCOPE IO pathology platform for ivonescimab immuno-oncology development.
• The AI-powered platform will analyze tumor microenvironments in routine tissue slides to support biomarker discovery and patient selection research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunit Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610232126PR_NEWS_USPR_____CN80304) on October 24, 2026, and is solely responsible for the information contained therein.